The antiphospholipid antibodies present in antiphospholipid syndrome (APS) are directed at
a number of phospholipid-binding proteins: β2 glycoprotein I (β2GPI), prothrombin, and so …

IgA antiphospholipid antibodies (aPL) are not currently recognized as formal laboratory
criteria for the Antiphospholipid Syndrome (APS). This is mainly due to methodological …

Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed
against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed …

Antiphospholipid syndrome (APS) is a hypercoagulation condition associated with the
incidence of heterogenic antiphospholipid antibodies (aPLs), which non-specifically affect …

Background Anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) immunoglobulin A
(IgA) antiphospholipid antibodies (aPL) have shown to associate with thrombosis and …

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis
and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the …

The antiphospholipid (antibody) syndrome (APS) is an autoimmune condition characterised
by a wide range of clinical features, but primarily identified as thrombotic and/or obstetric …

The role of antiphospholipid antibodies (aPL) associated with cardiovascular diseases has
been extensively studied in autoimmune patients, however it was largely unknown whether …

Antiprothrombin antibodies, measured with phosphatidylserine/prothrombin complex
(aPS/PT) ELISA, have been reported to be associated with antiphospholipid syndrome …

The COVID-19 pandemic has raised questions about indirect impact in pregnant women on
the development of their future children. Investigating the characteristics of lipid metabolism …